{"componentChunkName":"component---src-templates-chapter-level-2-chapter-level-2-tsx","path":"/topics/prostatitis-chronic/prescribing-information/azithromycin/","result":{"pageContext":{"chapter":{"id":"2a603a06-dc49-5056-bf3b-1492b6300035","slug":"azithromycin","fullItemName":"Azithromycin","depth":2,"htmlHeader":"<!-- begin field ce96324e-d157-4d0e-9eb1-a9fb00cffbe7 --><h2>Azithromycin</h2><!-- end field ce96324e-d157-4d0e-9eb1-a9fb00cffbe7 -->","summary":"","htmlStringContent":"<!-- begin item 0f5178b8-5562-445a-85ff-a9fb00cffba3 --><!-- end item 0f5178b8-5562-445a-85ff-a9fb00cffba3 -->","topic":{"id":"c4c9527b-558e-5f8e-bc17-8e290dcde258","topicId":"e7c47213-5bd0-4104-8047-fdc108a48fed","topicName":"Prostatitis - chronic","slug":"prostatitis-chronic","lastRevised":"Last revised in September 2019","chapters":[{"id":"db8b7f60-5def-5da6-8f5a-97b134fe81af","fullItemName":"Summary","slug":"summary","subChapters":[]},{"id":"261b0e99-ad07-59aa-82ad-fa8c5e297c03","fullItemName":"Have I got the right topic?","slug":"have-i-got-the-right-topic","subChapters":[]},{"id":"191f6daf-33c8-5a36-9298-deb70f2118f9","fullItemName":"How up-to-date is this topic?","slug":"how-up-to-date-is-this-topic","subChapters":[{"id":"3196f07a-652b-594b-a01b-c5adf6819612","slug":"changes","fullItemName":"Changes"},{"id":"cb3c96a5-276d-5602-88a2-6fe23e9db68a","slug":"update","fullItemName":"Update"}]},{"id":"71da42c9-a078-59ae-90c6-752133b53212","fullItemName":"Goals and outcome measures","slug":"goals-outcome-measures","subChapters":[{"id":"aec7f6cf-32f0-5cb8-997e-4fef498eea4a","slug":"goals","fullItemName":"Goals"},{"id":"3afbaae7-ae1e-5df4-87a4-e8fcadd24ce9","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"87d31fcb-2e1a-5f5f-b2b3-3cebf26dbf5e","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"b0e77d09-ef7a-52ce-a61d-d74872fcd77f","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"73212593-e3d8-52ec-9384-1ee26a9e0290","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"59aaca07-0adb-5035-afea-fd747f067bc8","slug":"nice-quality-standards","fullItemName":"NICE quality standards"}]},{"id":"864060e0-9a10-5069-9b80-daf6551f49b4","fullItemName":"Background information","slug":"background-information","subChapters":[{"id":"120b86df-be4c-54e8-ab8a-7edcad60de73","slug":"definition","fullItemName":"Definition"},{"id":"a35c2de7-75f2-59f4-9df6-6115e92ac1f7","slug":"causes","fullItemName":"Causes"},{"id":"3aa8e065-e5d9-587b-92fa-8e1824a53f6e","slug":"prevalence","fullItemName":"Prevalence"},{"id":"34308471-71dc-5ccd-bf18-de90bce09174","slug":"prognosis","fullItemName":"Prognosis"},{"id":"6bcf89d2-7be0-5893-bcef-296b2b00b23e","slug":"complications","fullItemName":"Complications"}]},{"id":"e0b8b43d-8013-564a-b64b-23866b939127","fullItemName":"Diagnosis","slug":"diagnosis","subChapters":[{"id":"5803967f-79d1-596c-8fb4-58eb0581f053","slug":"when-to-suspect","fullItemName":"When to suspect"},{"id":"2901399a-1d1a-5b5e-ba74-a8e2973308cc","slug":"assessment","fullItemName":"Assessment"},{"id":"07fe1726-43db-50e8-854d-9e8d2048398c","slug":"investigations","fullItemName":"Investigations"},{"id":"3cf83ed6-63bf-58b4-97f7-98cd7d6815da","slug":"differential-diagnosis","fullItemName":"Differential diagnosis"}]},{"id":"dc9db115-7acf-5a8a-9dd1-f6bf8dd93454","fullItemName":"Management","slug":"management","subChapters":[{"id":"dbc1e2eb-5ed6-5e3b-9aa6-6f4a53bae15e","slug":"managing-chronic-prostatitis","fullItemName":"Scenario: Managing chronic prostatitis"}]},{"id":"c609cd7e-5825-5ffb-83e8-ba87b7f7806d","fullItemName":"Prescribing information","slug":"prescribing-information","subChapters":[{"id":"035b193a-907c-5212-99c7-e8a8926b1594","slug":"paracetamol-ibuprofen-codeine","fullItemName":"Paracetamol, ibuprofen, and codeine"},{"id":"f4e7b4f3-38ad-521e-bb43-4c48ac37724f","slug":"alpha-blockers","fullItemName":"Alpha-blockers"},{"id":"24c19a61-fe65-594c-a4e5-ab3b500281e4","slug":"trimethoprim","fullItemName":"Trimethoprim"},{"id":"2a603a06-dc49-5056-bf3b-1492b6300035","slug":"azithromycin","fullItemName":"Azithromycin"}]},{"id":"39e951b0-a3a9-5bae-8465-8d5b1ac9504b","fullItemName":"Supporting evidence","slug":"supporting-evidence","subChapters":[]},{"id":"d8eb1d6d-d3f5-593e-bcbc-4214d26beee2","fullItemName":"How this topic was developed","slug":"how-this-topic-was-developed","subChapters":[{"id":"a9bd9455-225c-5705-8101-1b4f3177119c","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"3984c05f-a691-5d06-9587-785be5667206","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"e6bedf32-0ef7-5118-b6e2-fc3c2631a8c3","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"1405259b-4bc7-5907-af93-234db06e958f","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"ad44cee6-1d13-5c9e-9587-6de26a5b22fd","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"160b464d-6dc9-5bb7-9156-90aa025b130c","fullItemName":"References","slug":"references","subChapters":[]}]},"parentChapter":{"id":"c609cd7e-5825-5ffb-83e8-ba87b7f7806d","slug":"prescribing-information","fullItemName":"Prescribing information"},"subChapters":[{"id":"fd66a89e-1d96-5153-808f-67be492ff410","slug":"contraindications","fullItemName":"Contraindications","depth":3,"htmlHeader":"<!-- begin field 1524e831-c17b-454b-a90e-a9fb00d05ba2 --><h3>Cautions and precautions</h3><!-- end field 1524e831-c17b-454b-a90e-a9fb00d05ba2 -->","summary":"","htmlStringContent":"<!-- begin item 207e31d2-2e36-452d-8f97-a9fb00d05b86 --><!-- begin field 3083699a-7146-4450-bea0-a9fb00d05ba2 --><ul><li>Use azithromycin with caution in people who may be predisposed to prolongation of the QT interval. This includes people:<ul><li>With congenital or documented acquired QT prolongation.</li><li>Currently receiving treatment with other active substances known to prolong the QT interval such as antiarrhythmics of classes IA and III.</li><li>With electrolyte disturbance, particularly in cases of hypokalaemia and hypomagnesaemia.</li><li>With clinically relevant bradycardia, cardiac arrhythmia, or severe cardiac insufficiency.</li></ul></li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/prostatitis-chronic/references/\">ABPI Medicines Compendium, 2013b</a>] </p><ul><li>Prolonged QT interval or cardiac repolarization have been reported with other macrolides and a similar effect with azithromycin has not been ruled out.</li></ul><!-- end field 3083699a-7146-4450-bea0-a9fb00d05ba2 --><!-- end item 207e31d2-2e36-452d-8f97-a9fb00d05b86 -->","subChapters":[]},{"id":"65277aa6-8a96-5465-94c6-b8b0e01862c3","slug":"adverse-effects","fullItemName":"Adverse effects","depth":3,"htmlHeader":"<!-- begin field 566cb44b-8d1b-405f-9167-a9fb00d06bf7 --><h3>Adverse effects</h3><!-- end field 566cb44b-8d1b-405f-9167-a9fb00d06bf7 -->","summary":"","htmlStringContent":"<!-- begin item 3868b539-cf5f-45a9-ba0a-a9fb00d06bc8 --><!-- begin field 78b73474-5909-4de6-a79c-a9fb00d06bf7 --><ul><li>Nausea, vomiting, diarrhoea, and abdominal discomfort are the most common adverse effects of all the macrolides, but are milder and less frequent with azithromycin than with erythromycin.</li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/prostatitis-chronic/references/\">ABPI Medicines Compendium, 2013b</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/prostatitis-chronic/references/\">BNF 65, 2013</a>] </p><!-- end field 78b73474-5909-4de6-a79c-a9fb00d06bf7 --><!-- end item 3868b539-cf5f-45a9-ba0a-a9fb00d06bc8 -->","subChapters":[]},{"id":"5912ce6e-37e9-56cf-b9aa-a09e085a5c62","slug":"interactions","fullItemName":"Interactions","depth":3,"htmlHeader":"<!-- begin field bfb60847-0a52-4d9d-b325-a9fb00d08060 --><h3>Interactions</h3><!-- end field bfb60847-0a52-4d9d-b325-a9fb00d08060 -->","summary":"","htmlStringContent":"<!-- begin item 8edac835-8168-4bf0-b8c6-a9fb00d08044 --><!-- begin field 17257dca-5433-43b6-9b4a-a9fb00d08060 --><ul><li><strong>Warfarin </strong>— occasionally and unpredictably, the effects of warfarin may be markedly increased by macrolides.<ul><li>Monitor the international normalized ratio (INR), and adjust the warfarin dose accordingly.</li></ul></li><li><strong>Statins </strong>— the manufacturer reports post-marketing cases of rhabdomyolysis in people taking azithromycin with statins, although this appears to be less common than with other macrolides.<ul><li>Advise the person to report any muscle pain, tenderness, or weakness.</li></ul></li><li><strong>Ciclosporin </strong>— azithromycin can affect clearance of ciclosporin. If co-administration of these drugs is necessary, ciclosporin levels should be monitored and the dose adjusted accordingly.</li><li><strong>Drugs that prolong the QT interval</strong> (such as amiodarone, sotalol, terfenadine, and amisulpride) — all macrolides can prolong the QT interval, and concomitant use of drugs that prolong the QT interval is not recommended.<ul><li>Use an alternative antibiotic and/or seek advice from a microbiologist.</li></ul></li><li><strong>Drugs that cause hypokalaemia</strong> (such as diuretics, corticosteroids, short-acting beta-<sub>2</sub> agonists) — hypokalaemia is a risk factor for QT prolongation.<ul><li>Use an alternative antibiotic and/or seek advice from a microbiologist.</li></ul></li><li><strong>Colchicine </strong>—  concomitant administration has been reported to increase levels of P-glycoprotein substrate. This protein has been linked to barriers to successful chemotherapy treatment in cancer.</li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/prostatitis-chronic/references/\">ABPI, 2016</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/prostatitis-chronic/references/\">BNF 71, 2016</a>] </p><!-- end field 17257dca-5433-43b6-9b4a-a9fb00d08060 --><!-- end item 8edac835-8168-4bf0-b8c6-a9fb00d08044 -->","subChapters":[]}]}}},"staticQueryHashes":["3666801979"]}